Phase II Trial of Capecitabine and Weekly Docetaxel for Metastatic Castrate Resistant Prostate Cancer

PURPOSE: Synergy is observed with the combination of capecitabine and docetaxel due to docetaxel mediated up-regulation of thymidine phosphorylase. A phase II trial was performed with the combination for metastatic, castrate resistant prostate cancer. MATERIALS AND METHODS: Eligible patients had met...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Vaishampayan, Ulka N., Marur, Shanthi, Heilbrun, Lance K., Cher, Michael L., Dickow, Brenda, Smith, Daryn W., Al Hasan, Samir A., Eliason, James
Formato: Artigo
Lenguaje:Inglês
Publicado: 2009
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3869185/
https://ncbi.nlm.nih.gov/pubmed/19447430
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.juro.2009.02.105
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares